About This Project
The Ebola outbreak in west Africa has been declared a global emergency by the WHO with over 1,000 victims and no approved therapies. OncoSynergy is developing a readily manufactured experimental cancer drug, OS2966, which coincidentally targets the receptor hijacked by ebola to infect cells. This project aims to demonstrate that OS2966 inhibits ebola infection of human cells thus providing the impetus for expediting OS2966 for treatment of ebola.
Browse Other Projects on Experiment
Performance-enhancing substances: How do male black widows use chemical cues to gain a competitive advantage?
For a male black widow spider, life is a series of deadly challenges. He must first make a dangerous...